Sectors

ALGS
Aligos Therapeutics, Inc.
7.28
1 x 7.20
25 x 7.95
bid
ask
-
0.37
4.84%
undefined @ 04:00 PM
7.25 -0.03 (0.41%)
Ytd-21.89%
1y-3.83%
7.15
day range
7.80
3.98
52 week range
13.69
Open7.58Prev Close7.65Low7.15High7.80Mkt Cap45.05M
Vol236.59KAvg Vol183.89KEPS-7.30P/E-1.00Forward P/E-3.30
Beta2.12Short Ratio0.50Inst. Own48.86%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg5.38200-d Avg7.251yr Est103.33
Income Statement
Total Revenue27.78M
Revenues (USD)27.78M
Gross Profit27.78M
Operating Expenses29.67M
Research and Development Expense24.05M
Selling, General and Administrative Expense5.62M
Operating Income-1.89M
Interest Expense-221.00K
Income Tax Expense2.81M
Net Income-1.50M
Net Income Common Stock-1.50M
Net Income Common Stock (USD)-1.50M
Consolidated Income-1.50M
Earnings per Basic Share-0.14
Earnings per Basic Share (USD)-0.14
Earnings per Diluted Share-0.14
Earning Before Interest & Taxes (EBIT)1.09M
Earning Before Interest & Taxes (USD)1.09M
Weighted Average Shares10.43M
Weighted Average Shares Diluted10.43M
Balance Sheet
Cash and Equivalents30.42M
Cash and Equivalents (USD)30.42M
Trade and Non-Trade Receivables27.78M
Current Assets62.13M
Property, Plant & Equipment Net3.44M
Total Assets66.33M
Debt Current3.22M
Total Debt3.50M
Current Liabilities28.34M
Debt Non-Current288.00K
Total Liabilities34.44M
Accumulated Retained Earnings (Deficit)-666.74M
Accumulated Other Comprehensive Income437.00K
Shareholders Equity31.88M
Shareholders Equity (USD)31.88M
Assets Non-Current4.20M
Total Debt (USD)3.50M
Liabilities Non-Current6.10M
Trade and Non-Trade Payables6.43M
Cash Flow
Depreciation, Amortization & Accretion728.00K
Net Cash Flow from Financing220.00K
Net Cash Flow / Change in Cash & Cash Equivalents269.00K
Capital Expenditure-1000
Issuance (Purchase) of Equity Shares236.00K
Issuance (Repayment) of Debt Securities -16.00K
Net Cash Flow from Investing25.00M
Net Cash Flow - Investment Acquisitions and Disposals25.00M
Net Cash Flow from Operations-24.95M
Share Based Compensation1.36M